Document is current
Any future updates will be listed below
-
Authors
Laatsch, Jonathan https://orcid.org/0009-0004-5557-8894
Stein, Frederike https://orcid.org/0000-0002-5052-6022
Maier, Simon https://orcid.org/0000-0002-7326-7422
Matthies, Swantje https://orcid.org/0000-0002-0395-7882
Sobanski, Esther https://orcid.org/0000-0001-7824-3959
Alm, Barbara
Tebartz van Elst, Ludger https://orcid.org/0000-0002-2274-5447
Krug, Axel https://orcid.org/0000-0002-0564-2497
Philipsen, Alexandra https://orcid.org/0000-0001-6876-518X
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01GV0605, 01GV0606)
- License Information
-
More Information
Article History
Received: 7 January 2025
Revised: 9 September 2025
Accepted: 2 October 2025
First Online: 17 October 2025
Competing interests
: J.L., A.K., F.S., S.M., Sw.M. declare no competing financial interests. A.P. declares that she served on advisory boards, gave lectures, performed phase-3 studies, and received travel grants within the last five years from MEDICE Arzneimittel, Pütter GmbH and Co KG, Takeda, Boehringer, Janssen-Cilag, and receives royalties from books published by Elsevier, Hogrefe, MWV, Kohlhammer, Karger, Oxford Press, Thieme, Springer, Schattauer. She is a member of the German ADHD Guideline Group and author of the Updated European Consensus Statement. E.S. declares that she received a travel grant from Takeda and a grant from BMBF. B.A. declares that she has held lectures for Takeda. L.T.v.E. reported serving on advisory boards, delivering lectures, and receiving travel grants within the last 3 years from Eli Lilly and Co, Janssen-Cilag, Novartis, Shire, UCB, GlaxoSmithKline, Servier Laboratories, Janssen, and Cyberonic.
